Press Releases

WASHINGTON, Aug. 29, 2019 /PRNewswire/ --

SANTA BARBARA, Calif., Aug. 29, 2019 /PRNewswire/ -- BD (Becton, Dickinson and Company), a leading global medical technology company, along with Direct Relief and the National Association of Community Health Centers (

NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nektar Therapeutics (NASDAQ: NKTR) from February 15, 2019 through August 8, 2019, inclusive (the "Class Period"). The l

WINOOSKI, Vt., Aug 29, 2019 /PRNewswire/ -- Marathon Health, LLC, a provider of employer healthcare services, today announced Bruce Hochstadt, MD, as executive vice presid

ARLINGTON, Va., Aug. 29, 2019 /PRNewswire/ -- Michael Fraser, Chief Executive Officer of the Association of State and Territorial Health Officials (ASTHO), issued the following statement in response to the Surgeon General's advisory on marijuana use and its impact on the developing brain:

LAS VEGAS, Aug. 29, 2019 /PRNewswire/ -- Greenery Map, a mobile app and website, creates tri-lingual platform for marijuana users to find cannabis strains that can help them achieve t

GRAND RAPIDS, Mich., Aug. 29, 2019 /PRNewswire/ -- Advent Physical Therapy, a service of Mercy Health and Alliance Physical Therapy Partners, is pleased to announce the opening of their new outpatient rehabilitation clinic in Ada, Michigan. The new location is part of several health provider groups and services, bringing quality car

SILVER SPRING, Md., Aug. 29, 2019 /PRNewswire/ -- Today, the U.S. Food and Drug Administration is recommending that duodenoscope manufact

NEW YORK, Aug. 29, 2019 /PRNewswire/ -- Northwell Health, New York State's largest health care provider and private employer, has selected

NEW YORK, Aug. 29, 2019 /PRNewswire/ -- The Lupus Research Alliance is excited to share the good news that a potential new medicine for lupus, anifrolumab, reduced disease activity versus placebo in a second Phase III study. Anifrolumab is a therapeutic antibody that blocks type I interferons, a molecule that promotes lupus inflammation. Over 15 studies funded by the Lu